Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 4, 2011, Pages 403-407

  Wong, Eric T ^a   Gautam, Shiva ^a   Malchow, Christopher ^a   Lun, Melody ^b   Pan, Edward ^c   Brem, Steven ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bevacizumab; Glioblastoma; Meta analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; LOMUSTINE;

AGE DISTRIBUTION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 79953876016     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0037     Document Type: Article

References (26)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioblastoma multiforme. J Clin Oncol 1999;17:2572-2578. (Pubitemid 29368260)
2. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563. (Pubitemid 40017699)
3. Jain RK. Normalizing tumor vasculature with anti-angiogenesis therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989. (Pubitemid 32937367)
4. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol 2005;7:Abstract 369.
5. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729. (Pubitemid 350086473)
6. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-4721. (Pubitemid 350086472)
7. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
9. De Groot JF, Piao Y. Anti-VEGF but not VEGF receptor inhibitor therapy prolongs survival and blocks myeloid cell recruitment to orthotopic glioblastoma [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; April 17-21, 2010; Washington, DC. Philadelphia, Pa. AACR. Abstract 2279.
10. Scott BJ, Quant EC, McNamara MB, et al. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 2010;12:603-607.
11. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
12. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
13. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, and anti-vascular endothelial growth receptor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434. (Pubitemid 36910021)
14. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose escalation trial of bevacizumab in previously treated breast cancer. Semin Oncol 2003;30:117-124. (Pubitemid 37433402)
15. Chamberlain MC. Correspondence: bevacizumab plus irinotecan for recurrent malignant glioma. J Clin Oncol 2008;26:1012-1013. (Pubitemid 351398097)
16. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 2008;109:268-272.
17. Almubarak M, Newton M, Altaha R. Reintroduction of bevacizumab in combination with pegylated liposomal doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. J Oncol 2008;2008:942618.
18. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008;88:339-347.
19. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-2273. (Pubitemid 351628638)
20. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-163.
21. Kang TY, Jin T, Elinzano H, et al. Irinotecan and bevacizumab in progressive primary brain tumors, and evaluation of efficacy and safety. J Neurooncol 2008;89:113-118.
22. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180.
23. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma. Neurology 2009;72:1217-1222.
24. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and pattern of recurrence. Neurology 2008;70:779-787.
25. Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours. Acta Oncologica 2009;48:52-58.
26. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety, and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-336.